Methodology of Screening New Antibiotics: Present Status and Prospects

Due to extensive distribution of pathogen resistance to available pharmaceuticals and serious problems in the treatment of various infections and tumor diseases, the necessity of new antibiotics is urgent. The basic methodological approaches to chemical synthesis of antibiotics and screening of new antibiotics among natural products, mainly among microbial secondary metabolites, are considered in the review. Since the natural compounds are very much diverse, screening of such substances gives a good opportunity to discover antibiotics of various chemical structure and mechanism of action. Such an approach followed by chemical or biological transformation, is capable of providing the health care with new effective pharmaceuticals. The review is mainly concentrated on screening of natural products and methodological problems, such as: isolation of microbial producers from the habitats, cultivation of microorganisms producing appropriate substances, isolation and chemical characterization of microbial metabolites, identification of the biological activity of the metabolites. The main attention is paid to the problems of microbial secondary metabolism and design of new models for screening biologically active compounds. The last achievements in the field of antibiotics and most perspective approaches to future investigations are discussed. The main methodological approach to isolation and cultivation of the producers remains actual and needs constant improvement. The increase of the screening efficiency can be achieved by more rapid chemical identification of antibiotics and design of new screening models based on the biological activity detection.

antibiotic screening, antimicrobials, antifungals, antivirals, antitumors, sterol biosynthesis inhibitors, targets, new antibiotics, microbial models for antibiotic screening, microbial test-systems, secondary metabolism, producer cultivation, miniaturization, antibiotic recovery and identification

1. Shallcross L.J., Davies S.C. The World Health Assembly resolution on antimicrobial resistance. J Antimicrob Chemother 2014; 69: 11: 2883-2885.

2. Monnet D.L. Raising awareness about prudent use of antibiotics: a necessity for the European Union. Enferm Infecc Microbiol Clin 2010; 28: Suppl: 4: 1-3.

3. Livermore D.M. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39: 4: 283-294.

4. Magiorakos A.P., Srinivasan A., Carey R.B. et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18: 3: 268-281.

5. Ruiz-Camps I., Cuenca-Estrella M. Antifungals for systemic use. Enferm Infecc Microbiol Clin 2009; 27: 6: 353-362.

6. Awakawa T. The International Conference of Natural Product Biosynthesis (ICNPB, 8th US-Japan seminar on the Biosynthesis of Natural Products). J Antibiot (Tokyo) 2012; 65: 11: 587-590.

7. Zhang Q., Li S., Chen Y. et al. New diketopiperazine derivatives from a deep-sea-derived Nocardiopsis alba SCSIO 03039. J Antibiot (Tokyo) 2013; 66: 1: 31-36.

8. Орлова Т.И., Булгакова В.Г., Полин А.Н. Вторичные метаболиты микроорганизмов - потенциальный резерв фармацевтических препаратов. Антибиотики и химиотер 2014; 3-4; 38-44.

9. Тренин A.C., Дудник Ю.В. Твердофазная система РНК-зависимой ДНК-полимеразы в поиске антибиотиков - потенциальных ингибиторов ВИЧ. Антибиотики и химиотер 2005; 50: 10-11: 4- 12

10. Тренин A.C. Микробные метаболиты - ингибиторы биосинтеза стеролов, их химическое разнообразие и особенности механизма действия. Биоорган хим 2013; 39: 6: 633-657

11. Bérdy J. Bioactive microbial metabolites. J Antibiot (Tokyo) 2005; 58: 1: 1-26.

12. Bérdy J. Thoughts and facts about antibiotics: where we are now and where we are heading. J Antibiot (Tokyo) 2012; 65: 8: 385-395.

13. Demain A.L., Sanchez S. Microbial drug discovery: 80 years of progress. J. Antibiot (Tokyo) 2009; 62: 1: 5-16.

14. Freire-Moran L., Aronsson B., Manz C. et al. Critical shortage of new antibiotics in development against multidrug-resistant bacteria. Time to react is now. Drug Resist. Updat 2011; 14: 2: 118-124.

15. Clardy J., Fischbach M.A., Currie C.R. The natural history of antibiotics. Curr Biol 2009; 19: 11: 437-441.

16. Coates A.R., Hu Y. Novel approaches to developing new antibiotics for bacterial infections. Br J Pharmacol 2007; 152: 8: 1147-1154.

17. Aminov R.I. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol 2010; 1: 134: 1-7.

18. Brötz-Oesterhelt H., Sass P. Postgenomic strategies in antibacterial drug discovery. Future Microbiol 2010; 5: 10: 1553-1579.

19. Егоров H.C. Основы учения об антибиотиках. 6-е изд. 2004. М.: Изд. МГУ; Наука, 528.

20. Koehn F.E. High impact technologies for natural products screening. Prog Drug Res 2008; 65: 177-210.

21. Molinari G. Natural products in drug discovery: present status and perspectives. Adv Exp Med Biol 2009; 655: 13-27.

22. Donadio S., Maffioli S., Monciardini P. et al. Antibiotic discovery in the twenty-first century: current trends and future perspectives. J Antibiot (Tokyo) 2010; 63: 8: 423-430.

23. Genilloud O., González I., Salazar O. et al. Current approaches to exploit actinomycetes as a source of novel natural products. J Ind Microbiol Biotechnol 2011; 38: 3: 375-389.

24. Leeds J.A., Schmitt E.K., Krastel P. Recent developments in antibacterial drug discovery: microbe-derived natural products-from collection to the clinic. Expert Opin Investig Drugs 2006; 15: 3: 211-226.

25. Li J.W., Vederas J.C. Drug discovery and natural products: end of an era or an endless frontier? Science 2009; 325: 5937: 161-165.

26. Somanadhan B., Kotturi S.R., Leong C.Y. et al. Isolation and synthesis of falcitidin, a novel myxobacterial-derived acyltetrapeptide with activity against the malaria target falcipain-2. J Antibiot (Tokyo) 2013; 66: 5: 259-264.

27. Singh S.B., Young K. New antibiotic structures from fermentations. Expert Opin Ther Pat 2010; 20: 10: 1359-1371.

28. Sunazuka T., Hirose T., Omura S. Efficient total synthesis of novel bioactive microbial metabolites. Acc Chem Res 2008; 41: 2: 302-314.

29. Сазыкин Ю.О., Бибикова М.В., Иванов В.П. и др. Технология скрининга вторичных микробных метаболитов: к эволюции методологии. Антибиотики и химиотер 2002; 47: 10: 25-31

30. Феофилова Е.П., Алехин А.И., Гончаров Н.Г. и др. Фундаментальные основы микологии и создание лекарственных препаратов из мицелиальных грибов. М.: Национальная академия микологии: 2013; 152

31. Yamazaki Y., Someno T., Igarashi M. et al. Androprostamines A and B, the new anti-prostate cancer agents produced by Streptomyces sp. MK932-CF8. J Antibiot (Tokyo) 2015; 68: 4: 279-285.

32. Singh S.B., Pelaez F. Biodiversity, chemical diversity and drug discovery. Prog Drug Res 2008; 65: 141: 143-174.

33. Zanella F., Lorens J.B., Link W. High content screening: seeing is believing. Trends Biotechnol 2010; 28: 5: 237-245.

34. Berrue F., Withers S.T., Haltli B. et al. Chemical screening method for the rapid identification of microbial sources of marine invertebrate-associated metabolites. Mar Drugs 2011; 9: 3: 369-381.

35. Blondelle S.E., Lohner K. Optimization and high-throughput screening of antimicrobial peptides. Curr Pharm Des 2010; 16: 28: 3204-3211.

36. Alksne L.E., Dunman P.M. Target-based antimicrobial drug discovery. Methods Mol Biol 2008; 431: 271-283.

37. Тренин A.C. Микробные модели в поиске ингибиторов биосинтеза стеролов. Антибиотики и химиотер 2013; 58: 7-8: 3-14

38. Rahman H., Austin B., Mitchell W.J. et al. Novel anti-infective compounds from marine bacteria. Mar Drugs 2010; 8: 3: 498-518.

39. Tiwari K., Gupta R.K. Rare actinomycetes: a potential storehouse for novel antibiotics. Crit Rev Biotechnol 2012 Jun; 32: 2: 108-132.

40. Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Microbiol Mol Biol Rev 2004; 68: 4: 669-685.

41. Hu Y., Shamaei-Tousi A., Liu Y., Coates A. A new approach for the discovery of antibiotics by targeting non-multiplying bacteria: a novel topical antibiotic for staphylococcal infections. PLoS One 2010; 5: 7: P.e11818.

42. Gillespie D.E., Brady S.F., Bettermann A.D. et al. Isolation of antibiotics turbomycin A and B from a metagenomic library of soil microbial DNA. Appl Environ Microbiol 2002; 68: 9: 4301-4306.

43. Brady S.F., Simmons L., Kim J.H., Schmidt E.W. Metagenomic approaches to natural products from free-living and symbiotic organisms. Nat Prod Rep 2009; 26: 11: 1488-1503.

44. Hirota-Takahata Y., Kozuma S., Kuraya N. et al. Pedopeptins, novel inhibitors of LPS: Taxonomy of producing organism, fermentation, isolation, physicochemical properties and structural elucidation. J Antibiot (Tokyo) 2014; 67: 3: 243-251.

45. Raina S., De Vizio D., Odell M. et al. Microbial quorum sensing: a tool or a target for antimicrobial therapy?. Biotechnol Appl Biochem 2009; 54: 2: 65-84.

46. Sanchez S., Demain A.L. Metabolic regulation and overproduction of primary metabolites. Microb Biotechnol 2008; 1: 4: 283-319.

47. Amano S.I., Sakurai T., Endo K. et al. A cryptic antibiotic triggered by monensin. J Antibiot (Tokyo) 2011; 64: 10: 703.

48. Булгакова В.Г., Виноградова К.A., Орлова Т.И. и др. Действие антибиотиков как сигнальных молекул. Антибиотики и химиотер 2014; 59: 1-2: 36-43.

49. Challis G.L., Hopwood D.A. Synergy and contingency as driving forces for the evolution of multiple secondary metabolite production by Streptomyces species. Proc Natl Acad Sci USA 2003; 100: Suppl 2: 14555-14561.

50. Rigali S., Titgemeyer F., Barends S. et al. Feast or famine: the global regulator DasR links nutrient stress to antibiotic production by Streptomyces. EMBO Rep 2008; 9: 7: 670-675.

51. Sänchez S., Chávez A., Forero A. et al. Carbon source regulation of antibiotic production. J Antibiot (Tokyo) 2010; 63: 8: 442-459.

52. Стоянова Л.Г., Левина H.В. Регуляция синтеза бактериоцина рекомбинантного штамма Lactococcus lactis subsp. lactis F-116 компонентным составом среды. Микробиология. 2006; 75: 3: 286-291.

53. Ruiz B., Chávez A., Forero A. et al. Production of microbial secondary metabolites: regulation by the carbon source. Crit Rev Microbiol 2010; 36: 2: 146-167.

54. Duetz W.A., Witholt B. Effectiveness of orbital shaking for the aeration of suspended bacterial cultures in square-deepwell microtiter plates. Biochem Eng J 2001; 7: 113-115.

55. Dieting U., Trauthwein H., Zimmermann H. High-throughput screening in the climatic chamber. Elements Degussa Sci News 2005; 11: 14-18.

56. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Approved Standard 2nd edn CLSI document M27-A2 Clinical and Laboratory Standards Institute: Wayne, PA, 2002.

57. Кубанова A.A., Степанова Ж.В., Гуськова Т.А. и др. Методические указания по изучению противогрибковой активности лекарственных средств. В кн.: Руководство по проведению доклинических исследований лекарственных средств. Часть первая / Под ред. А.Н. Миронова. М.: Гриф и К, 2012; 944: 578-586.

58. Тренин A.C. Микробная тест-система для поиска ингибиторов биосинтеза стеролов. Антибиотики и химиотер 2013; 58: 3-4: 3-9

59. Тренин A.C. Микробная модель Halobacterium salinarum для поиска ингибиторов биосинтеза стеролов. Антибиотики и химиотер 2013; 58: 5-6: 3-10

60. Тренин A.C., Двигун E.A., Бычкова O.П., Лавренов C.H. Микробная модель Halobacterium salinarum в отборе синтетических аналогов антибиотика турбомицина А, обладающих противоопухолевым действием. Антибиотики и химиотер 2013; 58: 9-10: 3-7

61. Bode H.B., Bethe B., Hųfs R., Zeeck A. Big effects from small changes: possible ways to explore nature’s chemical diversity. Chembiochem 2002; 3: 7: 619-627.

62. Hopwood D.A. Cracking the polyketide code. PLoS Biol. 2004. V.2. N.2. E35. P.0166-0169. - Режим доступа: 10.1371/journal.pbio.0020035 - PMID:14966534.

63. Kotowska M. Application of molecular biology for the discovery of biosynthetic genes of polyketide and peptide antibiotics produced by actinomycetes. Postepy Biochem 2005; 51: 3: 345-352.

64. Егоров A.M. Антибиотики: прошлое, настоящее и будущее препаратов для лечения инфекционных болезней. Ведом науч центра экспер средств мед прим 2007; 3: 1-6.

65. Medema M.H., Kottmann R., Yilmaz P. et al. Minimum information about a biosynthetic gene cluster. Nat Chem Biol 2015 Aug; 11: 9: 625- 631.

66. Olano C., Méndez C., Salas J.A. Molecular insights on the biosynthesis of antitumour compounds by actinomycetes. Microb Biotechnol 2011; 4: 2: 144-164.

67. Nishida H., Beppu T., Ueda K. Whole-genome comparison clarifies close phylogenetic relationships between the phyla Dictyoglomi and Thermotogae. Genomics. 2011. Nov; 98; 5: 370-375.

68. Ma S.M., Li J.W, Choi J.W. et al. Complete reconstitution of a highly reducing iterative polyketide synthase. Science 2009: 326: 5952: 589-592.

69. Caffrey P., Aparicio J.F., Malpartida F., Zotchev S.B. Biosynthetic engineering of polyene macrolides towards generation of improved antifungal and antiparasitic agents. Curr Top Med Chem 2008; 8: 8: 639-653.

70. Schirmer A., Gadkari R., Reeves C.D. et al. Metagenomic analysis reveals diverse polyketide synthase gene clusters in microorganisms associated with the marine sponge Discodermia dissoluta. Appl Environ Microbiol 2005; 71: 8: 4840-4849.

71. Hopwood D.A. How do antibiotic-producing bacteria ensure their selfresistance before antibiotic biosynthesis incapacitates them? Mol Microbiol 2007; 63: 4: 937-940.

72. Méndez C., Künzel E., Lipata F. et al. Oviedomycin, an unusual angucy-clinone encoded by genes of the oleandomycin-producer Streptomyces antibioticus ATCC11891. J Nat Prod 2002; 65; 5: 779-782.

73. Shawky R.M., Puk O., Wietzorrek A. et al. The border sequence of the balhimycin biosynthesis gene cluster from Amycolatopsis balhimycina contains bbr, encoding a StrR-like pathway-specific regulator. J Mol Microbiol Biotechnol 2007; 13: 1-3: 76-88.

74. Gupta S.K., Padmanabhan B.R., Diene S.M. et al. ARG-ANNOT, a new bioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother 2014; 58: 1: 212-220.

75. Preobrazhenskaya M.N., Olsufyeva E.N., Tevyashova A.N. et al. Synthesis and study of the antifungal activity of new mono- and di-substituted derivatives of a genetically engineered polyene antibiotic 28, 29-didehydro nystatin A1 (S44HP). J Antibiot (Tokyo) 2010; 63: 2: 55-64.

76. Macone A.B., Caruso B.K., Leahy R.G. et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 2014; 58: 2: 1127-1135.

77. Chen X., Wei P., Fan L. et al. Generation of high-yield rapamycin-pro-ducing strains through protoplasts-related techniques. Appl Microbiol Biotechnol 2009; 83: 3: 507-512.

78. Тренин A.C., Федорова Г.Б., Лайко A.В., Дудник Ю.В. Увеличение продукции эремомицина в результате регенерации и УФ-облучения протопластов Amycolatopsis orientalis subsp. eremomycini. Антибиотики и химиотер 2001; 46: 3: 6-11.

79. Nakashima T., Iwatsuki M., Ochiai J. et al. Mangromicins A and B: structure and antitrypanosomal activity of two new cyclopentadecane compounds from Lechevalieria aerocolonigenes K10-0216. J Antibiot (Tokyo) 2014; 67: 3: 253-260.

80. Testa C.A., Johnson L.J. A whole-cell phenotypic screening platform for identifying methylerythritol phosphate pathway-selective inhibitors as novel antibacterial agents. Antimicrob Agents Chemother 2012 Sep; 56: 9: 4906-4913.

81. Kahan B.D. Forty years of publication of transplantation proceedings- the second decade: the cyclosporine revolution. Transplant Proc 2009; 41: 5: 1423-1437.

82. Iwasaki S., Omura S. Search for protein farnesyltransferase inhibitors of microbial origin: our strategy and results as well as the results obtained by other groups. J Antibiot (Tokyo) 2007; 60: 1: 1-12.

83. Hiramatsu K., Igarashi M., Morimoto Y. et al. Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature. Int J Antimicrob Agents 2012; 39: 6: 478-485.

84. Bugg T.D., Braddick D., Dowson C.G., Roper D.I. Bacterial cell wall assembly: still an attractive antibacterial target. Trends Biotechnol 2011; 29: 4: 167-173.

85. Бибикова М.В., Грамматикова Н.Э., Катлинский A.В. и др. Влияние природных гиполипидемических соединений на формирование биоплёнок штаммами рода Pseudomonas. Антибиотики и химиотер 2009; 54: 1-2: 10-13.

86. Тренин A.C., Терехова Л.П., Толстых И.В. и др. Отбор микробных вторичных метаболитов - ингибиторов биосинтеза холестерина с помощью культуры клеток гепатобластомы G2. Антибиотики и химиотер 2003; 48: 1: 3-8

87. Arai Y., Iinuma H., Ikeda Y. et al. Migracins A and B, new inhibitors of cancer cell migration, produced by Streptomyces sp. J Antibiot (Tokyo) 2013; 66: 4: 225-230.

88. Moy T.I., Conery A.L., Larkins-Ford J. et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 2009; 4: 7: 527-533.

89. Zhang B., Watts K.M., Hodge D. et al. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry 2011; 50: 17: 3570-3577.

90. Soppa J. From genomes to function: Haloarchaea as model organisms. Microbiology 2006; 152: 3: 585-590.

91. Терехова Л.П., Галатенко O.A., Тренин A.C. и др. Выделение и изучение антибиотика ИНА-1132 (хлоротрицина), образуемого штаммом Streptomyces baarnensis. Антибиотики и химиотер 2008; 53: 7-8: 3-7

92. Шашков A.C., Цветков Д.E., Лапчинская O.A. и др. Строение, спектры ЯМР 1Н и 13Сибиологическая активность антибиотика ИНА-1278, родственного ирумамицину и продуцируемого экспериментальным штаммом Streptomyces sp. № 1278. Известия РАН. Серия химическая. 2011; 60: 11: 2365-2370

93. Тренин A.C., Кац Н.Ю., Двигун E.A., Бычкова O.M., Краснопольская Л.М. Базидиальные грибы Kuehneromyces mutabilis, Flammulina velutipes и Lentinus edodes, как возможные продуценты ингибиторов биосинтеза стеролов. Успехи мед микол 2014; 12: 353-354

94. Cтепанова Е.В., Штиль A.A., Лавренов C.H. и др. Соли трис (1-алкилиндол-3-ил) метилия - новый класс противоопухолевых соединений. Известия Академии наук. Серия химическая. 2010; 12: 1-9

95. Yao X., Li C., Zhang J., Lu C.D. г-Glutamyl spermine synthetase PauA2 as a potential target of antibiotic development against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2012; 56: 10: 5309-5314

96. Huband M.D., Bradford P.A., Otterson L.G. et al. In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against gram-positive, fastidious gram-negative, and atypical bacteria. Antimicrob Agents Chemother 2015; 59: 1: 467-474

97. Therien A.G., Huber J.L., Wilson K.E. et al. Broadening the spectrum of /З-lactam antibiotics through inhibition of signal peptidase type I. Antimicrob Agents Chemother 2012; 56: 9: 4662-4670.

98. Cox G., Koteva K., Wright G.D. An unusual class of anthracyclines potentiate gram-positive antibiotics in intrinsically resistant gram-negative bacteria. J Antimicrob Chemother 2014; 69: 7: 1844-1855.

99. Cushnie T.P., Cushnie B., Lamb A.J. Alkaloids: an overview of their antibacterial, antibiotic-enhancing and antivirulence activities. Int J Antimicrob Agents 2014; 44: 5: 377-386.

100. Otto M.P., Martin E., Badiou C. et al. Effects of subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2013; 68: 7: 1524-1532.

101. Diep B.A., Afasizheva A., Le H.N., et al. Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia. J Infect Dis 2013; 208:1: 75-82.

102. Khodaverdian V., Pesho M., Truitt B. et al. Discovery of antivirulence agents against methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2013; 57: 8: 3645-3652.

103. Maiolo E.M., Furustrand Tafin U., Borens O., Trampuz A. Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on plank-tonic and biofilm Candida species determined by microcalorimetry. Antimicrob Agents Chemother 2014; 58: 5: 2709-2717.

104. Arita-Morioka K., Yamanaka K., Mizunoe Y. et al. Novel strategy for biofilm inhibition by using small molecules targeting molecular chaperone DnaK. Antimicrob Agents Chemother 2015; 59: 1: 633-641.

105. Baugh S., Phillips C.R., Ekanayaka A.S. et al. Inhibition of multidrug efflux as a strategy to prevent biofilm formation. J Antimicrob Chemother 2014; 69: 3: 673-681.

106. Marcone G.L., Carrano L., Marinelli F., Beltrametti F. Protoplast preparation and reversion to the normal filamentous growth in antibiotic-producing uncommon actinomycetes. J Antibiot (Tokyo) 2010; 63: 2: 83-88.

107. Walkty A., Adam H., Baxter M. et al. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrob Agents Chemother 2014; 58: 5: 2554-2563.

108. Huang E., Yousef A.E. Paenibacterin, a novel broad-spectrum lipopep-tide antibiotic, neutralises endotoxins and promotes survival in a murine model of Pseudomonas aeruginosa-induced sepsis. Int J Antimicrob Agents 2014; 44: 1. P.74-77.

109. Qian C.D., Wu X.C., Teng Y. et al. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria. Antimicrob Agents Chemother 2012; 56: 3: 1458-1465.

110. Hernandez V., Crépin T., Palencia A. et al. Discovery of a novel class of boron-based antibacterials with activity against gram-negative bacteria. Antimicrob Agents Chemother 2013; 57: 3: 1394-1403.